An Open-Label, Randomized, Single Application, Two-Period Crossover, Pivotal Bioequivalence Study to Evaluate the Bioequivalence of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Subjects

Trial Profile

An Open-Label, Randomized, Single Application, Two-Period Crossover, Pivotal Bioequivalence Study to Evaluate the Bioequivalence of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Pain
  • Focus Pharmacokinetics; Registrational
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 14 Sep 2016 Status changed from recruiting to completed.
    • 01 Apr 2016 Planned End Date changed from 1 Jan 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
    • 01 Apr 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top